SCHEMBL314866

SCHEMBL314866

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO[Si](C)(C)C(C)(C)C)O[C@H]2n1ccc2c(Cc3ccccc3)ncnc21

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 8/20 0.39
WDR77 Q9BQA1 8/20 0.39
RXFP1 Q9HBX9 1/20 0.38
PI4KA P42356 1/20 0.37
PI4K2B Q8TCG2 1/20 0.37
PI4K2A Q9BTU6 1/20 0.37
PI4KB Q9UBF8 1/20 0.37
SLC29A1 Q99808 1/20 0.37
P2RX1 P51575 1/20 0.36
P2RX3 P56373 1/20 0.36
P2RX4 Q99571 1/20 0.36
ADK P55263 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314858 0.89 RXFP1 (0.41) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL324410 0.88 PI4KA (0.43) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL325332 0.86 ALDH1A1 (0.44) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL18009882 0.85 PRMT5 (0.42) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL24687531 0.84 RXFP1 (0.41) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL18572224 0.84 PRMT5 (0.52) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL10131056 0.84 RXFP1 (0.41) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL18009694 0.84 RXFP1 (0.41) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL18535190 0.84 RXFP1 (0.41) PRMT5WDR77RXFP1PI4KAPI4K2B
SCHEMBL18009779 0.82 RXFP1 (0.40) PRMT5WDR77RXFP1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3133080-B1 NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2018-08-01 EP disclosed
EP-3133080-A1 NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2017-02-22 EP disclosed
EP-2231689-B1 NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES ACAD OF SCIENCE CZECH REPUBLIC (CZ) 2016-07-20 EP disclosed
US-8093226-B2 Cytostatic 7-deazapurine nucleosides INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) 2012-01-10 US disclosed
US-20090203637-A1 NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203637-A1 NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES TYMP, TYMS, DPYD PRMT5 245/4885WDR77 172/4885RXFP1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.